Tocilizumab for refractory organising pneumonia associated with Sjögren's disease

BMJ Case Reports

Volumn 2015, Issue , 2015, Pages

  Justet, Aurelien ^a,b   Ottaviani, Sebastien ^a   Dieudé, Philippe ^a   Taillé, Camille ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN; INTERLEUKIN 6 RECEPTOR; LA ANTIBODY; METHOTREXATE; PREDNISONE; RITUXIMAB; RO ANTIBODY; STEROID; TOCILIZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PREDNISOLONE;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; GASTROESOPHAGEAL REFLUX; HUMAN; LOBAR PNEUMONIA; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; MIDDLE AGED; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; SALIVARY GLAND BIOPSY; SCHIRMER TEST; SIALOADENITIS; SJOEGREN SYNDROME; COMBINATION DRUG THERAPY; COMPLICATION; CRYPTOGENIC ORGANIZING PNEUMONIA; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; CRYPTOGENIC ORGANIZING PNEUMONIA; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISOLONE; RECEPTORS, INTERLEUKIN-6; RITUXIMAB; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84930009883     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2014-209076     Document Type: Article

References (18)

1. Nannini C, Jebakumar AJ, Crowson CS, et al. Primary Sjogren's syndrome 1976- 2005 and associated interstitial lung disease: A population-based study of incidence and mortality. BMJ Open 2013; 3: E003569.
2. Henriet AC, Diot E, Marchand-Adam S, et al. Organising pneumonia can be the inaugural manifestation in connective tissue diseases, including Sjogren's syndrome. Eur Respir Rev Off J Eur Respir Soc 2010; 19: 161-3.
3. Yoo JW, Song JW, Jang SJ, et al. Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia. Rheumatol Oxf Engl 2011; 50: 932-8.
4. Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: Current perspective. Curr Opin Rheumatol 2011; 23: 273-7.
5. Shiboski SC, Shiboski CH, Criswell LA, et al. Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren's syndrome: A data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012; 64: 475-87.
6. Majeski EI, Paintlia MK, Lopez AD, et al. Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes. Am J Pathol 2003; 163: 1467-79.
7. Cordier JF. Organising pneumonia. Thorax 2000; 55: 318-28.
8. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130: 1489-95.
9. Schlesinger C, Koss MN. The organizing pneumonias: A critical review of current concepts and treatment. Treat Respir Med 2006; 5: 193-206.
10. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012; 8: 399-411.
11. Komai T, Shoda H, Yamaguchi K et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Mod Rheumatol 2013.
12. Elhai M, Meunier M, Matucci-Cerinic M, et al. EUSTAR (EULAR Scleroderma Trials and Research group). Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study. Ann Rheum Dis 2013; 72: 1217-20.
13. Andres M, Vela P, Romera C. Marked improvement of lung rheumatoid nodules after treatment with tocilizumab. Rheumatol Oxf Engl 2012; 51: 1132-4.
14. Keidel SM, Hoyles RK, Wilkinson NM. Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra. Rheumatol Oxf Engl 2014; 53: 573-4.
15. Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2012; 32: 4023-6.
16. Wendling D, Vidon C, Godfrin-Valnet M, et al. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine 2013; 80: 670-1.
17. Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-A systematic literature review. Rheumatology (Oxford) 2011; 50: 2297-305.
18. Ikegawa K, Hanaoka M, Ushiki A, et al. A case of organizing pneumonia induced by tocilizumab. Intern Med 2011; 50: 2191-3.